Company intelligence / Profile preview

3a-diagnostics

Frickenhausen, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

3a-diagnostics has developed peptide-based biosensor point-of-care tests for bacterial and viral infectious diseases and a high-throughput biosensor screening platform. It contributed to Covid-ID Lab, a rapid 25‑minute PCR-based COVID-19 point-of-care test with CE mark in Europe, and has EU registration for an oral biosensor product for mouth infections and oral inflammation.[1][3]

Therapeutic areas: Infectious DiseasesGastroenterology
Modalities: DeviceNon-pharmacological therapy
Industry: Molecular Diagnostics

Partnerships

XPhyto Therapeutics (now Bionxt Solutions) – acquirer and commercialization partner for biosensor technologies and Covid-ID Lab point-of-care PCR platform

Beyond the preview

Go deeper on 3a-diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3a-diagnostics.

Explore the full profile